Littérature scientifique sur le sujet « Acute mania »
Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres
Sommaire
Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Acute mania ».
À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.
Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.
Articles de revues sur le sujet "Acute mania"
1
Holtzer, Christopher D., et Stephen A. Echaves. « Valproate in the Treatment of Acute Mania ». Journal of Pharmacy Technology 12, no 1 (janvier 1996) : 6–11. http://dx.doi.org/10.1177/875512259601200104.
Texte intégralRésumé :
Objective: To determine whether valproate is effective for the acute treatment of mania. Data Sources: Pertinent literature was identified through a MEDLINE search. Study Selection: Blinded, controlled, or other high-quality trials with adequate sample size evaluating valproate in the treatment of acute mania were selected. Data Extraction: Study selection for the review was based on the quality of the trial and the clinical endpoint of control of acute manic symptoms using valproate. Data Synthesis: Acute manic episodes in bipolar disease are disabling and dangerous. A minority of acutely manic patients either do not respond to treatment with lithium or cannot tolerate its adverse effects. Valproate is a viable but slightly less effective alternative in the patients who cannot use lithium. Conclusions: Combined analysis of all studies examined in this article yields a success rate of 54% for valproate in the treatment of acute mania. This efficacy rate recommends valproate as suitable alternative treatment for acutely manic patients who do not respond to lithium or cannot tolerate its adverse effects.
2
Yatham, Lakshmi N., Peter F. Liddle, Jonathan Erez, Marcia Kauer-Sant'Anna, Raymond W. Lam, Miguel Imperial, Vesna Sossi et Thomas J. Ruth. « Brain serotonin-2 receptors in acute mania ». British Journal of Psychiatry 196, no 1 (janvier 2010) : 47–51. http://dx.doi.org/10.1192/bjp.bp.108.057919.
Texte intégralRésumé :
BackgroundAlthough 5-hydroxytryptamine (5-HT) has been implicated in mania, the precise alterations in the 5-HT system remain elusive.AimsTo assess brain 5-HT2 receptors in drug-free individuals experiencing a manic episode in comparison with healthy volunteers using positron emission tomography (PET).MethodParticipants (n = 10) with DSM–IV bipolar I disorder – manic episode and healthy controls (n = 10) underwent [18F]- setoperone scans. The differences in 5-HT2 receptor binding potential between the two groups were determined using statistical parametric mapping (SPM) analysis.ResultsAge was a significant correlate with 5-HT2 receptor binding potential with a similar magnitude of correlation in both groups. The SPM analysis with age as a covariate showed that the individuals with current mania had significantly lower 5-HT2 receptor binding potential in frontal, temporal, parietal and occipital cortical regions, with changes more prominent in the right cortical regions compared with controls.ConclusionsThis study suggests that brain 5-HT∗2 receptors are decreased in people with acute mania.
3
Frye, Mark A. « Treatment Guidelines for Acute Manic and Mixed Episodes of Bipolar Disorder ». CNS Spectrums 14, S15 (décembre 2009) : 8–11. http://dx.doi.org/10.1017/s1092852900004028.
Texte intégralRésumé :
Bipolar disorder is a lifelong condition, and pharmacotherapy is essential to its long-term management. Once a comprehensive diagnostic assessment for acute or mixed mania has been completed, it is important to look at an evidence-based data set to guide treatment selection for mood stabilization.For most patients, lifetime adherence to pharmacotherapy is necessary for maximal mood stability. Pharmacotherapy is the primary treatment for bipolar disorder, as it has been found to be efficacious in treating acute episodes and preventing future episodes of bipolar I disorder. Combination therapy, including at least one mood stabilizer, may be necessary to treat acute depression and mania and to further prevent both depressive and manic recurrences. The goal is to minimize frequency, duration, and severity of depressive and manic symptoms with a treatment regimen, ideally a combination of pharmacotherapy and psychotherapy, that is positioned to maximize treatment adherence and minimize side effects.This discussion reviews some treatment guidelines for acute manic and mixed episodes associated with bipolar I disorder. Through the context of a case study, this discussion will attempt to provide an understanding and appreciation of Food and Drug Administration-approved and non-FDA-approved treatments for acute mania. In addition, the impact of alcohol as an example of drugs of abuse and its impact on the presentation of acute mania will be discussed.
4
Duman, Berker, Adnan Kuşman, Burçin Çolak, Filiz Çay Şenler et Hakan Kumbasar. « Tamoxifen-induced acute mania : A case report ». Journal of Oncology Pharmacy Practice 26, no 8 (11 avril 2020) : 2025–27. http://dx.doi.org/10.1177/1078155220915959.
Texte intégralRésumé :
Introduction Tamoxifen is widely used for the treatment of hormone-responsive breast cancer, osteoporosis, and post-menopausal symptoms. Also, tamoxifen is currently under investigation for its anti-manic properties. In this article, we report a case who developed manic episode following the initiation of tamoxifen and remitted with discontinuation of the medication. Case Report A 58-year-old woman was diagnosed with breast cancer. Pathologic diagnosis was invasive ductal carcinoma. Following bilateral total mastectomy operation, trastuzumab was initiated with intervals of 21 days. Five days before the fourth application of trastuzumab, tamoxifen was added. On the sixth day following the initiation of tamoxifen, manic symptoms were developed and she was diagnosed as acute mania. Management and Outcome The oncology department suggested withdrawing tamoxifen due to a possible association between tamoxifen initiation and behavioral symptoms. Manic symptoms were rapidly (approximately 24 h) improved following cessation of tamoxifen. Psychiatric evaluation on the fifth day following cessation of tamoxifen revealed no manic symptoms. An aromatase inhibitor-exemestane was initiated and she showed no side effects with this medication since then. Discussion To our knowledge, this is the first case report of probable tamoxifen-induced mania. Our case report at least indicates that there were possibly some patients who were sensitive to the tamoxifen’s nervous system effects, mainly to manic effects. In conclusion, clinicians should be aware of these rare behavioral adverse effects of tamoxifen.
5
Khanna, Sumant, Eduard Vieta, Benjamin Lyons, Fred Grossman, Mariëlle Eerdekens et Michelle Kramer. « Risperidone in the treatment of acute mania ». British Journal of Psychiatry 187, no 3 (septembre 2005) : 229–34. http://dx.doi.org/10.1192/bjp.187.3.229.
Texte intégralRésumé :
BackgroundSevere mania is life-threatening, carries an increased risk of suicide and has a serious impact on patients and their families. Efficient and rapid control of episodes of acute mania is needed.AimsTo evaluate the safety and efficacy of risperidone monotherapy for acute mania.MethodIn a 3-week, randomised, double-blind trial, 290 in-patients with bipolar l disorder with current manic or mixed episode and a baseline Young Mania Rating Scale (YMRS) score of 20 or more received flexible doses of risperidone (1–6 mg per day) or placebo.ResultsRisperidone was received by 146 patients and placebo by 144. Their mean baselineYMRS score was 37. 2 (s. e. =0. 5). Significantly greater improvements were observed with risperidone than with placebo at weeks l and 2 and at end-point (total YMRS: P<0. 01). Extrapyramidal symptoms were the most frequently reported adverse events in the risperidone group.ConclusionsIn patients with severe manic symptoms, risperidone produced significant improvements in YMRS scores as early as week 1 and substantial changes at end-point. Treatment was well tolerated.
6
Thomas, Pierre. « Treatment options for acute mania ». European Psychiatry 18, S1 (décembre 2003) : 13s—18s. http://dx.doi.org/10.1016/s0924-9338(03)80011-1.
Texte intégralRésumé :
Mood disorders that have no medical or pharmacological causes are divided into depressive disorders (unipolar, or major depressive disorder) and bipolar disorders. In bipolar disorders, both depressive and manic episodes occur sequentially.A manic episode is characterised as an abnormally excited mood that is experienced by a patient for a distinct period (at least a week). Diagnosis of mania requires that a patient’s work and social life be significantly affected, or that the patient needs hospitalisation. Diagnosis also requires the presence of three or more of the following symptoms: inflated self-esteem or grandiosity; decreased need for sleep; increased talkativeness; racing thoughts/ideas; distraction; increased goal-directed activity; excessive involvement in pleasurable activities [1].
7
Zajecka, John M. « Acute Mania ». Psychiatric Annals 33, no 12 (1 décembre 2003) : 786–95. http://dx.doi.org/10.3928/0048-5713-20031201-06.
Texte intégral
8
Dose, Matthias, et Hinderk M. Emrich. « Acute Mania ». CNS Drugs 3, no 6 (juin 1995) : 427–35. http://dx.doi.org/10.2165/00023210-199503060-00003.
Texte intégral
9
van Rossum, Inge, Josep Maria Haro, Diederik Tenback, Maarten Boomsma, Iris Goetz, Eduard Vieta et Jim van Os. « Stability and treatment outcome of distinct classes of mania ». European Psychiatry 23, no 5 (août 2008) : 360–67. http://dx.doi.org/10.1016/j.eurpsy.2008.02.005.
Texte intégralRésumé :
AbstractBackgroundPsychopathological heterogeneity in manic syndromes may in part reflect underlying latent classes with characteristic outcome patterns. Differential treatment course and outcome after 12 weeks of treatment were examined for three distinct classes of patients with acute mania in bipolar disorder.Subjects and methodsThree thousand four hundred and twenty-five patients with acute mania were divided into three distinct mania classes: ‘Typical’, ‘Psychotic’ and ‘Dual’ (i.e. comorbid substance use) mania. Persistence of class differences and social outcomes were examined, using multilevel regression analyses and odds ratios.ResultsThe three classes showed substantial stability post-baseline in the pattern of associations with class-characteristic variables. Psychotic and Dual mania predicted poorer outcome in terms of psychosis comorbidity and overall bipolar and mania severity, while Dual mania additionally predicted poorer outcome of alcohol and substance abuse. Worse social outcomes were observed for both Dual and Psychotic mania.ConclusionThe identified distinct classes are stable and associated with differential treatment outcome. Overall, Dual and Psychotic mania show less favourable outcomes compared to Typical mania. These findings additionally give rise to concern on the generalisability of randomized clinical trials RCTs.
10
Ghabi, H., M. Karoui, S. Ben Salem, R. Kamoun et F. Ellouz. « Acute mania in patient under tamoxifen ». European Psychiatry 64, S1 (avril 2021) : S433. http://dx.doi.org/10.1192/j.eurpsy.2021.1155.
Texte intégralRésumé :
IntroductionTamoxifen is an antioestrogen agent used in breast cancer treatment. According to some guidelines, this molecular was also proposed for the treatment of acute mania. In fact, Tamoxifen inhibits the intracellular action of the protein kinase C (PKC), which is the direct target in the treatment of mania episodes. Lithium and valproate have also the same action.ObjectivesWe aimed to show the case of an acute mania under an inhibitor PKC treatment and insisted that other studies are recommended.MethodsCase report description and research on medline, pubmed with the keywords: Tamoxifen, Bipolar disorder, protein kinase C,mania.ResultsWe reported a case of a 53-year-old woman with past history of unipolar depression. In 2018 when she was diagnosed with breast cancer. She received antidepressant drugs but she interrupted the treatment after a few months. She was treated for her breast cancer with mastectomy, radiotherapy, and 20 mg per day of Tamoxifen prescribed since Mars 2018. She had been admitted in June 2019 in our department for acute mania. The patient received Tamoxifen as it was prescribed. She was not taking any concomitant medications. No history of drug abuse was reported. Medical examination, laboratory, and radiological investigations did not indicate any medical pathology.ConclusionsIn our case, Tamoxifen had not ovoid the acute mania in spite of its Known anti-manic properties as reported in the literature. Possible neurobiological effect of tamoxifen on the nervous system should be studied to evaluate the safety of this treatment mainly in patients with bipolar disorder.
Thèses sur le sujet "Acute mania"
1
Garcia, Anne-Laetitia. « Maria Callas en acte : étude historique et rhétorique d'une actio opératique ». Paris 3, 2008. http://www.theses.fr/2008PA030107.
Texte intégralRésumé :
Entre 1947 et 1965, Maria Callas développe à l’opéra non seulement un chant hors norme qui réactive une ancienne technique, le bel canto, mais aussi un art dramatique consommé. L’essence théâtrale du genre opératique jaillit à nouveau sur son plateau : le corps actant s’unit au corps chantant, le voir s’unit à l’entendre. L’étude des cinq mises en scène de Luchino Visconti et des jeux de correspondances établis par le metteur en scène, points de départ de notre réflexion, ouvre des axes permettant de saisir la réception contemporaine et d’appréhender l’efficacité d’hier. D’une généalogie des monstres sacrés et des techniques actoriales à la problématique de l’Ut Pictura Theatrum, des confrontations analogiques avec différentes références des arts scéniques, des beaux-arts et du cinéma ouvrent des perspectives d’analyse et mettent à jour des notions esthétiques fondamentales. Ainsi, la technè rhétorique se révèle un outil précieux pour comprendre la construction de ce corps en acte, particulièrement avec la notion d’actio (mise en voix et en corps d’un discours), au cœur de l’art de l’orateur, de la construction et de la théorisation de jeu tragique à l’âge classique. Dans le questionnement des arts mimétiques qu’une telle étude implique, les notions de sublime et d’amplificatio s’imposent aussi pour déchiffrer une action scénique dilatée, véhémente et styliséeBetween 1947 and 1965, Maria Callas developed not only an unconventional style of operatic singing while reviving the bygone technique of bel canto, but also her consummate dramatic skills. With her, the dramatic essence of the operatic genre sprang forth anew on the stage : the acting body combined with the singing body, ‘seeing’ combined with ‘hearing’. The study of Luchino Visconti’s five operatic productions and of the correspondence effects he contrived as a director – the starting points of our analysis – opens up new paths which enable us to comprehend both today’s reception and yesterday’s efficacy. From a genealogy of public idols and acting techniques to the problematics of the Ut Pictura Theatrum, analogical confrontations with various references from the performing arts, the fine arts and the cinema, reveal prospects for analysis and bring to light fundamental aesthetic notions. Thus, the rhetorical technè turns out to be an invaluable tool so as to understand the construction of this acting body, especially with the notion of actio – the rendering of speech through the voice and the body – at the core of the orator’s art, of the construction and theorization of tragic acting in the classical age. Through the questioning of the mimetic arts involved by such a study, the notions of the sublime and amplificatio are also essential to the decoding of an expanded, vehement and stylized theatrical (/performing) action
2
Venâncio, Antonio Medeiros. « Toxicidade aguda e atividade antinociceptiva do óleo essencial do Ocimum basilicum L. (MANJERICÃO), em Mus musculus (camundongos) ». Universidade Federal de Sergipe, 2006. https://ri.ufs.br/handle/riufs/3806.
Texte intégralRésumé :
Coordenação de Aperfeiçoamento de Pessoal de Nível SuperiorThe aim of this study was to determine the acute toxicity and the antinociceptive action, of the Essential Oil obtained from leaves of Ocimum basilicum L. (LAMIACEAE), PI-197442, manjericão maria bonita . The Ocimum presents various species, used in the folk medicine, like antispasmodic, sedative and carminative, in agriculture as repellent of insects. The acute toxicity was determined by probit method using 5 groups (N=6) of mice, both genders. The LD50 was 0,532g/kg from the animals. The antinociceptive effect was studied by three models of nociception: The abdominal writhes induced by acetic acid 0,6% (i.p.), Hot Plate and the Test of Formalin. The OE increased the nociceptive effect dependent-dose in the concentrations 50, 100 and 200mg/kg in 48,02%, 64,48% and 77,49%, respectively, in the Test of Wrighting. In the Hot Plate, the OE increased the time of staying under the thermal stimulus in the times of 0, 15, 30 and 60 minutes. In the time of 15 min, was obtained the most significant effect. The morphine 10mg/kg was used as antinociception pattern. The antagonist Nalaxone opiod, reverted the effect of OE-50 in all tested times. In the Test of Formalin, the OE presented significant effect just in the second phase. The OE-200, in this phase, reduced the licking times of hind paw in 74,66%. These results showed that the OE of Ocimum basilicum L. presented high toxicity (i.p.) and showed peripherical and central antinociception activities.
O objetivo deste estudo foi determinar a toxicidade aguda e a ação antinociceptiva do Óleo Essencial (OE) obtido das folhas do Ocimum basilicum L. (LAMIACEAE), PI-197442, manjericão maria bonita . O gênero Ocimum apresenta várias espécies usadas na medicina popular como antiespasmódico, sedativo e carminativo, e na agricultura, como repelente de insetos. A DL-50 obtida pelo método dos probitos foi 0,532g/kg de peso de animal. O efeito antinociceptivo foi estudado usando três modelos de nocicepção: Contorções abdominais, induzidas pelo ácido acético 0,6% (i.p.); Placa quente e o Teste da formalina. O OE reduziu o efeito nociceptivo de maneira dose-dependente nas concentrações 50, 100 e 200mg/kg em 48,02%, 64,48% e 77,49%, respectivamente, no Teste das Contorções. Na Placa Quente, o OE-50 aumentou o tempo de permanência sob o estímulo térmico nos tempos 0, 15, 30 e 60 min. A morfina 10mg/kg foi usada como padrão de antinocicepção. O antagonista opióide, Naloxona, reverteu o efeito do OE-50 em todos os tempos testados. No Teste da Formalina, o OE apresentou efeito significativo apenas na 2ª fase. O OE 200mg/kg reduziu o tempo de lambida da pata traseira em 74,66%. Estes resultados mostraram que o OE do Ocimum basilicum L. tem alta toxicidade (i.p.) e apresenta atividade antinociceptiva periférica e central.
3
Combette, Charles. « Héros de bande dessinée : entre présence et absence ». Thesis, Bordeaux 3, 2013. http://www.theses.fr/2013BOR30053.
Texte intégralRésumé :
Qu’est-ce qu’un héros de bande dessinée ? Comment fonctionne-t-il ? Pourquoi est-il ainsi ? Ce sont là les trois questions principales que nous entendons traiter dans les pages de cette thèse. C’est principalement l’étude de la relation entre le lecteur et le héros qui va nous permettre de répondre. Cette relation, nous la nommons identification, elle est à la fois reconnaissance et projection. C’est dans ce double mouvement – du héros vers le lecteur, du lecteur vers le héros – que nous trouverons notre objet. Notre cheminement nous amènera à définir le héros tant de façon diachronique, en nous attardant sur son origine et son évolution historique (avec une attention particulière pour les productions et les réflexions de Rodolphe Töpffer), que de façon synchronique en le comparant aux héros d’autres médiums. Définissant le héros par son fonctionnement identificatoire, nous étudierons celui-ci en analysant les stratégies graphiques mises en œuvre par les auteurs de bandes dessinées pour que celui-ci se produise. Cela nous permettra enfin de tirer des conclusions esthétiques et éthiques de ce fonctionnement, et de préciser la nature de l’expérience de la bande dessinée. Ce travail de recherche fera donc appel, pour être mené à bien, à des outils provenant des domaines variés que sont l’analyse plastique, la sémiologie, l’esthétique, la philosophie, les études littéraires, etcWhat is a comic book hero? How does it work? Why is it so? These are the three main issues that we intend to cover in the pages of this thesis. This is mainly the study of the relationship between the reader and the hero that will allow us to respond. This relationship, we call identification, it is both recognition and projection. It is in this double movement - the hero to the reader, the reader to the hero - that we find our purpose. Our journey will take us to define the hero so diachronically, but to focus on its origin and historical development (with particular attention to the production and reflections Rodolphe Töpffer) as synchronically by comparing the heroes of other mediums. Defining the hero by identificatory function, we will study it by analyzing the graphic strategies implemented by the authors of comics for it to happen. This will allow us finally to draw aesthetic and ethical conclusions of this operation, and to specify the nature of the experience of the comic. This research will therefore appeal to be completed, tools from various fields such as plastic analysis, semiotics, aesthetics, philosophy, literary studies, etc
4
PURGATO, Marianna. « COMPARATIVE EFFICACY AND ACCEPTABILITYOF PHARMACOLOGICAL TREATMENTSFOR ACUTE MANIA:A MULTIPLE TREATMENTS META-ANALYSIS ». Doctoral thesis, 2012. http://hdl.handle.net/11562/394344.
Texte intégralRésumé :
Background: La mania è la caratteristica clinica che contraddistingue il disturbo bipolare. Ad oggi, non vi sono in letteratura evidenze forti e indicazioni chiare rispetto a quale trattamento farmacologico sia più adatto nella fase maniacale acuta del disturbo bipolare. L’obiettivo del presente lavoro è stato quello di condurre una revisione sistematica della letteratura per confrontare i farmaci più comunemente utilizzati in ambito clinico per il trattamento della mania, sia in termini di efficacia che di tollerabilità. I risultati degli studi inclusi sono stati inoltre analizzati utilizzando la tecnica della multiple treatments meta-analysis, che permette di effettuare una stima complessiva con confronti diretti e indiretti tra farmaci, ed arrivare ad avere una gerarchia dei trattamenti basata sulle evidenze.
Metodi: Sono stati inclusi studi clinici controllati e randomizzati (randomized controlled trial – RCT) in doppio cieco, che confrontavano un farmaco antimaniacale (antipsicotico o stabilizzante dell’umore) con un altro farmaco antimaniacale o placebo, come terapia in acuto della mania. Sono state raccolte evidenze per 14 farmaci, oltre al placebo: aripiprazolo, asenapina, carbamazepina, valproato, gabapentin, aloperidolo, lamotrigina, litio, olanzapina, paliperidone, quetiapina, risperidone, topiramato e ziprasidone. Sono stati inclusi solo studi che confrontassero trattamenti somministrati per via orale, sia in monoterapia che in associazione tra loro.
Risultati: Delle 582 referenze potenzialmente rilevanti, in totale 68 trial (tra cui 9 RCT non pubblicati) sono stati inclusi nella multiple treatments meta-analysis. Tutti i farmaci studiati sono risultati in maniera statisticamente significativa più efficaci rispetto al placebo, ad eccezione di gabapentin, lamotrigina e topiramato. In termini di acceptability, solo olanzapina, risperidone e quetiapina sono risultati significativamente meglio del placebo. Riguardo l’efficacia comparativa tra farmaci antimaniacali, l’aloperidolo è risultato essere il farmaco più efficace, rispetto a litio, quetiapina, aripiprazolo, carbamazepina, asenapina, valproato, ziprasidone, lamotrigina, topiramato e gabapentin. Risperidone e olanzapina hanno mostrato un profilo di efficacia molto simile, essendo entrambi più efficaci di valproato, ziprasidone, lamotrigina, topiramato e gabapentin. Topiramato e gabapentin hanno rivelato una minore efficacia rispetto a tutti gli altri farmaci antimaniacali. Riguardo alla tollerabilità, l’aloperidolo ha mostrato rispetto all’olanzapina un maggior tasso di drop-out dopo 3 settimane di trattamento. Il litio è risultato peggio di olanzapina, risperidone e quetiapina; la lamotrigina peggio di olanzapina e risperidone; il topiramato è stato peggio tollerato di molti altri trattamenti antimaniacali, come aloperidolo, olanzapina, risperidone, quetiapina, aripiprazolo, carbamazepina e valproato.
Conclusioni: Questa multiple treatments meta-analysis è il primo lavoro che effettua confronti diretti e indiretti tra trattamenti farmacologici per la mania acuta. I risultati di questa analisi hanno importanti implicazioni cliniche che dovrebbero essere considerate nella costruzione di linee-guida e raccomandazioni sui trattamenti farmacologici.Background: Mania is the hallmark feature of bipolar disorder. Clinically, mania can quickly escalate out of control, and cause severe disruption to the lives of individuals with the disorder. This is particularly important as mania can result in disturbed behavior that, when extreme, can be a risk to the safety of the patient and others. Mood stabilizers and antipsychotic agents have long been the mainstay of treatment of acute mania. In recent years several atypical antipsychotics agents have been licensed to treat mania (aripiprazole, olanzapine, risperidone and quetiapine). However, conventional meta-analyses have shown inconsistent results for efficacy of pharmacological treatments for acute mania. The aim of this study was to compare the efficacy and acceptability of pharmacological treatments for acute mania, in order to inform clinical practice and mental health policies. We carried out a multiple-treatments meta-analysis (MTM), a statistical technique that allows both direct and indirect comparisons to be undertaken, even when two of the treatments have not been directly compared. Methods: Double-blind randomized controlled trials (RCTs) comparing one active drug (antipsychotic, mood stabiliser or benzodiazepine) with another active drug (antipsychotic, mood stabiliser or benzodiazepine) or placebo as oral therapy in the treatment of acute mania were included. All combination and augmentation studies were included as well. Participants were patients aged 18 or older of both sexes with a primary diagnosis of acute mania or bipolar disorder (manic or mixed episode) according to the standardised diagnostic criteria used by the study authors. Overall efficacy was primarily measured as the mean change of the total score of the Young Mania Rating Scale (YMRS) from baseline to endpoint. We also estimated efficacy as the proportion of patients who responded to treatment (reduction of at least 50% on the total score between baseline and endpoint on a standardized rating scale for mania possibly YMRS). Acceptability was defined as the proportion of patients who left the study early for any reason, out of the total number of randomized patients. Results: We systematically reviewed 68 RCTs (16 073 participants) from 1980 to 2010, which compared any of the following 14 drugs at therapeutic dose range: aripiprazole, asenapine, carbamazepine, valproate, gabapentin, haloperidol, lamotrigine, lithium, olanzapine, quetiapine, risperidone, topiramate, and ziprasidone. 15 673 patients contributed to the efficacy analysis as continuous outcome (63 studies), 15 626 to the acceptability analysis (65 studies); for secondary outcome 12 649 patients (47 studies) contributed to efficacy analysis as dichotomous data. All anti-manic drugs –with exception of topiramate and gabapentin- showed significant efficacy than placebo. Antipsychotic drugs were significantly more effective than mood stabilizers. In terms of efficacy, haloperidol, risperidone, and olanzapine outperformed other drugs. In terms of dropouts, olanzapine, risperidone, and quetiapine were better than haloperidol. Risperidone, olanzapine, and haloperidol seem to be the best of the available options for the treatment of manic episodes. Conclusions: This MTM is the first analysis that incorporates direct and indirect comparisons between pharmacological treatments for acute mania. These findings have potential clinical implications that should be considered in the development of clinical practice guidelines
5
Morgan, Kylie A., University of Western Sydney, College of Arts et School of Communication Arts. « Music therapy in the management of acute psychosis ». 2007. http://handle.uws.edu.au:8081/1959.7/16371.
Texte intégralRésumé :
The management of acute psychosis is a constant challenge to the health care system, with only a limited amount of research providing data for allied health care practitioners. Despite anecdotal data indicating that music therapy may be an effective intervention, there have been few studies to date which provide any rigorous empirical evidence. This project aimed to test several hypotheses. The study has shown that music therapy is a valuable therapeutic adjunct to standard ward programs for the management of an acute psychotic episode resulting in shorter hospital stays, considerable cost savings and significant improvement in symptomatology as judged by the standardized measures employed. In addition, EFG testing while listening to self-chosen music demonstrated a reduction in dysfunctional brain wave activity. This project has highlighted the importance of music therapy in allied mental health care and opens up the need for further research into the management of such a large disease burden in Australia.Doctor of Philosophy (PhD)
6
Morgan, Kylie A. « Music therapy in the management of acute psychosis ». Thesis, 2007. http://handle.uws.edu.au:8081/1959.7/16371.
Texte intégralRésumé :
The management of acute psychosis is a constant challenge to the health care system, with only a limited amount of research providing data for allied health care practitioners. Despite anecdotal data indicating that music therapy may be an effective intervention, there have been few studies to date which provide any rigorous empirical evidence. This project aimed to test several hypotheses. The study has shown that music therapy is a valuable therapeutic adjunct to standard ward programs for the management of an acute psychotic episode resulting in shorter hospital stays, considerable cost savings and significant improvement in symptomatology as judged by the standardized measures employed. In addition, EFG testing while listening to self-chosen music demonstrated a reduction in dysfunctional brain wave activity. This project has highlighted the importance of music therapy in allied mental health care and opens up the need for further research into the management of such a large disease burden in Australia.
Livres sur le sujet "Acute mania"
1
National Institute for Clinical Excellence., dir. Olanzapine and valproate semisodium in the treatment of acute mania associated with bipolar I disorder. London : National Institute for Clinical Excellence, 2003.
Trouver le texte intégral
2
Rowling, J. K. Harry Potter and the Order of the Phoenix. Waterville, ME, USA : Thorndike Press, 2003.
Trouver le texte intégral
3
Rowling, J. K. Harry Potter und der Orden des Phönix. Hamburg, Germany : Carlsen, 2003.
Trouver le texte intégral
4
(translator), Gemma Rovira Ortega. Harry Potter y la Orden del Fenix. Navarra, España : Salamandra Publicacions Y Edicions, S.L., 2004.
Trouver le texte intégral
5
Rowling, J. K. Harry Potter és a Főnix Rendje. 2e éd. Budapest : Animus, 2005.
Trouver le texte intégral
6
Rowling, J. K. Harry Potter & Huoi Phưvong Hoàng. Thành phro Hso Chí Minh : NXB Trke, 2005.
Trouver le texte intégral
7
Rowling, J. K. Harry Potter and the Order of the Phoenix. New York, NY : Arthur A. Levine Books, 2003.
Trouver le texte intégral
8
Rowling, J. K. Harry Potter i l'orde del fènix. Barcelona, Spain : Editorial Empúries, 2004.
Trouver le texte intégral
9
Rowling, J. K. Harry Potter & Huoi Phưvong Hoàng. 3e éd. TP. Hso Chí Minh, Viet Nam : NXB Trke, 2007.
Trouver le texte intégral
10
Rowling, J. K. হ্যারি পটার অ্যান্ড দ্য অর্ডার অব দ্য ফিনিক্স. Ḍhākā : Aṅkura Prakāśanī, 2007.
Trouver le texte intégralChapitres de livres sur le sujet "Acute mania"
1
Keck, Paul E., Susan L. McElroy et John M. Hawkins. « Acute Mania ». Dans Bipolar Disorder, 285–93. Chichester, UK : John Wiley & Sons, Ltd, 2010. http://dx.doi.org/10.1002/9780470661277.ch22.
Texte intégral
2
Müller, Adolf A., Klaus-D. Stoll et Günter Wendt. « Oxcarbazepine in Acute Mania ». Dans Psychiatry the State of the Art, 495–500. Boston, MA : Springer US, 1985. http://dx.doi.org/10.1007/978-1-4613-2363-1_78.
Texte intégral
3
Allen, Melissa, Yasmin Gharbaoui, Chester Wu, Noha Abdel-Gawad et Mollie Gordon. « Sleep Disturbance During an Acute Manic Episode ». Dans Sleep Disorders in Selected Psychiatric Settings, 111–22. Cham : Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-59309-4_13.
Texte intégral
4
Dose, M., M. Weber, D. Bremer, C. Raptis et H. M. Emrich. « Action of Carbamazepine Suspension in Acute Manic Syndromes ». Dans New Directions in Affective Disorders, 545–48. New York, NY : Springer New York, 1989. http://dx.doi.org/10.1007/978-1-4612-3524-8_116.
Texte intégral
5
Cowen, Philip, Paul Harrison et Tom Burns. « Mood disorders ». Dans Shorter Oxford Textbook of Psychiatry, 205–53. Oxford University Press, 2012. http://dx.doi.org/10.1093/med/9780199605613.003.0010.
Texte intégralRésumé :
Chapter 10 discusses mood disorders, including clinical features, transcultural features, classification and differential diagnosis, epidemiology and aetiology, course and prognosis, acute treatment of depression and mania, longer-term treatment strategies, assessment and management of depressive disorders, assessment of mania, and management of manic patients.
6
« Bipolar illness ». Dans Oxford Handbook of Psychiatry, sous la direction de David Semple et Roger Smyth, 301–50. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199693887.003.0008.
Texte intégralRésumé :
Introduction Historical perspective Mania/manic episode Hypomania/hypomanic episode Bipolar spectrum disorder Bipolar (affective) disorder 1: classification Bipolar (affective) disorder 2: clinical notes Bipolar (affective) disorder 3: aetiology Bipolar (affective) disorder 4: management principles Other issues affecting management decisions Treatment of acute manic episodes Treatment of depressive episodes...
7
« Bipolar affective disorder (acute mania) in pregnancy ». Dans Basic Notes in Psychopharmacology, 117–18. CRC Press, 2018. http://dx.doi.org/10.1201/9781315377971-32.
Texte intégral
8
« Lithium in the treatment of acute mania ». Dans Lithium in Neuropsychiatry, 79–92. CRC Press, 2013. http://dx.doi.org/10.3109/9780203007051-15.
Texte intégral
9
Semple, David, et Roger Smyth. « Bipolar illness ». Dans Oxford Handbook of Psychiatry, 315–60. Oxford University Press, 2019. http://dx.doi.org/10.1093/med/9780198795551.003.0007.
Texte intégralRésumé :
This chapter covers bipolar illness. Definitions of mania and a manic episode are defined, as well as hypomania and hypomanic episodes. Bipolar spectrum disorder and different forms of bipolar disorder are classified, clinical presentations and notes described, and management principles discussed. Treatment of acute manic episodes and depressive episodes are covered, including prophylaxis and psychotherapeutic and pharmacological interventions (lithium, valproate, carbamazepine, and lamotrigine).
10
Curato, Lauren J. « An Energetic College Student ». Dans Psychiatric Emergencies, 91–98. Oxford University Press, 2022. http://dx.doi.org/10.1093/med/9780197544464.003.0014.
Texte intégralRésumé :
Bipolar disorder is a lifelong illness with episodes of mania or hypomania and major depression. Patients can present to the emergency department in any stage of their illness. In the acute manic phase of bipolar I, they tend to present dramatically, full of energy, psychotic, and disorganized. Alternatively, they may arrive due to depression, with hopelessness and thoughts of suicide. No matter which end of the spectrum from which they suffer, emergency providers’ first duty is to ensure their safety and investigate potential alternative causes of their illness. Cases of new-onset mania will require a more thorough investigation than manic episodes in patients with an established psychiatric diagnosis. Acute intervention with antipsychotics and benzodiazepines may be required while this investigation is ongoing. Admission or transfer to a psychiatric service with appropriate resources will be necessary for initial stabilization and implementation of the patient’s long-term treatment plan.
Actes de conférences sur le sujet "Acute mania"
1
Zhang, Xinyuan, Rui Duan, Jingcheng Du, Jing Huang, Yong Chen et Cui Tao. « Comparing Pharmacovigilance Outcomes Between FAERS and EMR Data for Acute Mania Patients ». Dans 2018 IEEE International Conference on Healthcare Informatics Workshop (ICHI-W). IEEE, 2018. http://dx.doi.org/10.1109/ichi-w.2018.00018.
Texte intégral
2
Del Sol Calderon, Pablo, María Martín García, Ángela Izquierdo de la Puente et Rocío Blanco Fernández. « Aripiprazol intramuscular como tratamiento eficaz para la agitación psicomotriz y manía aguda en paciente consumidor de cocaína. » Dans 22° Congreso de la Sociedad Española de Patología Dual (SEPD) 2020. SEPD, 2020. http://dx.doi.org/10.17579/sepd2020p125.
Texte intégralRésumé :
Introducción Varón de 27 años que ingresa en unidad de agudos por estado de agitación psicomotriz y episodio maniforme en probable relación con consumo de cocaína. Objetivo El objetivo de este caso es mostrar al airpiprazol inyectable 9.75 mg como tratamiento eficaz para la agitación psicomotriz y la manía aguda en un paciente consumidor de cocaína Metodología Presentación de caso y revisión de literatura Situacion actual El paciente acude a urgencias por episodio de alteración conductual en via publica. A su llegada presenta marcada agitación psicomotriz. Mantiene un discurso acelerado, taquipsíquico y con descarrilamiento en su discurso. El paciente no presenta antecedentes psiquiátricos. Reconoce un consumo elevado de cocaína desde hace 3 años con aumento en su consumo los últimos meses. Se administra aripiprazol 9.75 mg con diazepam 5 mg intramusculares con mejoría del estado de inquietud. Relata que desde hace una semana se encuentra con sensación de elevada energía junto con ideación delirante de contenido místico y megalomaníaco. Llevaba varios días sin ingerir alimentos, con un consumo diario de cocaína y con disminución importante de las horas de sueño. Se realiza exploración física con pruebas complementarias normales. Durante el ingreso se inicia aripiprazol intramuscular cada 8 horas durante 4 días para más tarde iniciar aripiprazol oral hasta 20 mg día. Los episodios de agitación fueron mitigándose y dándose con menor intensidad y reconducibles verbalmente. Progresivamente se fue organizando su discurso. Respecto al delirio fue distanciándose del contenido delirante pudiendo llegar a realizar crítica tanto de las ideas como del patrón de consumo. conclusión El aripirazol se ha mostrado como un fármaco eficaz para el manejo de episodios maniacos y de sintomatología psicótica. Su formulación intramuscular ha resultado una opción valida para el manejo de episodios de agitación psicomotriz y del tratamiento de sintomaotología maniforme.
3
Fernández Iturri, Melisa Valeria, LUCIA GARRIDO et VICTORIA EUGENIA MARTIN. « CANNABIS VERSUS PSICOSIS : A PROPÓSITO DE UN CASO ». Dans 22° Congreso de la Sociedad Española de Patología Dual (SEPD) 2020. SEPD, 2020. http://dx.doi.org/10.17579/sepd2020p082.
Texte intégralRésumé :
OBJETIVO: Discernir el grado de influencia del consumo en el desarrollo de un trastorno psicótico. MÉTODO: CASO CLÍNICO ANAMNESIS Varón de 20 años, consumidor habitual de cannabis desde los 16 años. Remitido desde atención primaria en 2016 por crisis de ansiedad y quejas somáticas, relacionadas a problemas con amigos, impresionando de ideas paranoides, dificultad para expresar la demanda, discurso concreto y contradictorio. Aumento de consumo con finalidad ansiolítica. Durante seguimiento no se objetivan síntomas psicóticos. Predominio de síntomas negativos: apatoabulia, anhedonia, disminución de atención y concentración. Tendencia al aplanamiento afectivo aunque cierta irritabilidad y agresividad contenida. Actitud de omnipontencia y escasa flexibilidad a la no concesión de sus deseos centrados en obtener dinero para consumir hachís. Deterioro de relaciones interpersonales, falta de proyectos vitales(ruptura biográfica). Ritmo de sueño desordendo. En 2020 acude a urgencias traído por el DCCU, valorado para ingreso el día anterior y se fugó. La madre refiere que pasa el día en la calle solo y fumando, la ha agredido por lo que ha puesto una orden de alejamiento y se queja de su insensibilidad. Escupe en repetidas ocasiones en relación a idea delirante, “cree que su madre le transmite mocos y es malo”, que tiene la capacidad de leer los pensamientos a su madre y que otros pueden leer sus pensamientos, que Dios “maneja” su pensamiento, “me manda pensamientos para que realice cosas”. EXPLORACIÓN Actitud colaboradora, niega y minimiza síntomas de descompensación y aumento de consumo. Se observa angustia, soliloquios y risas inmotivadas. Ideas delirantes paranoides y autorreferenciales. Alteración en la propiedad de pensamiento. Dificultades de organización del discurso. Conductas desorganizada. Heteroagresividad. Insomnio. JUICIO CLÍNICO: Trastorno psicótico a filiar, consumo perjudicial de cannabinoides. DIAGNÓSTICO DIFERENCIAL: Esquizofrenia simple. CONCLUSIONES: Se evidencia importante relación entre consumo y desarrollo de trastorno psicótico, siendo difícil precisar cuál comienza antes.
Rapports d'organisations sur le sujet "Acute mania"
1
Hsu, Tien-Wei, Chih-Sung Liang et Che-Sheng Chu. Heterogeneity and efficacy of mood stabilizer and atypical antipsychotic treatment for acute bipolar mania : a meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, janvier 2022. http://dx.doi.org/10.37766/inplasy2022.1.0002.
Texte intégral